InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar)
Catalog #SIM0028
Clone:
Denosumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Denosumab making it ideal for research use. This Denosumab biosimilar reacts with human RANKL (receptor activator of nuclear factor kappa-B ligand) also known as CD254 and TRANCE (TNF-related activation-induced cytokine). RANKL is a 35 kDa type II membrane protein that belongs to the TNF superfamily. RANKL is expressed on activated T lymphocytes in the lung, thymus, and lymph nodes and on osteoclasts. RANKL has been implicated in the regulation of T cell and dendritic cell interactions as well as osteoclast differentiation. Additionally, RANKL was found to be critical for osteoclast differentiation. Denosumab is an inhibitor of RANKL which functions by decreasing the development of osteoclasts.Specifications
Isotype | Human IgG1, Īŗ |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human RANKL |
Reported Applications |
Functional assays Flow Cytometry |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Production | Purified from cell culture supernatant |
Purification | Protein A |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |